Silence Therapeutics plc reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was GBP 9.1 million compared to GBP 3.64 million a year ago. Net loss was GBP 10.4 million compared to GBP 11.94 million a year ago. Basic loss per share from continuing operations was GBP 0.288 compared to GBP 0.399 a year ago.
For the six months, sales was GBP 20.48 million compared to GBP 9.37 million a year ago. Net loss was GBP 20.61 million compared to GBP 19.62 million a year ago. Basic loss per share from continuing operations was GBP 0.57 compared to GBP 0.657 a year ago.